<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660799</url>
  </required_header>
  <id_info>
    <org_study_id>YO42207</org_study_id>
    <nct_id>NCT04660799</nct_id>
  </id_info>
  <brief_title>A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter China-only study to investigate the PK, efficacy and safety of SC&#xD;
      rituximab versus IV rituximab, both in combination with CHOP (cyclophosphamide, doxorubicin,&#xD;
      vincristine, prednisone) in previously untreated participants with CD20 positive DLBCL.&#xD;
      Participants will be randomized to receive eight cycles of rituximab SC or rituximab IV&#xD;
      combined with six or eight cycles of standard CHOP chemotherapy. After the end of study&#xD;
      treatment, participants will be followed-up every 3 months for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of serum SC rituximab trough concentration (Ctrough,SC) and serum IV rituximab trough concentration (Ctrough,IV) during Cycle 7</measure>
    <time_frame>At Cycle 7, 21 days after study treatment administration (one Cycle=21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of observed SC and IV rituximab area under the serum concentration curve (AUCsc/AUCiv) during Cycle 7</measure>
    <time_frame>During Cycle 7 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) over the SC and IV rituximab dosing interval of Cycle 2</measure>
    <time_frame>During Cycle 2 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentration (Ctrough) of rituximab</measure>
    <time_frame>Cycle 1 through Cycle 8 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of rituximab</measure>
    <time_frame>Cycle 1 through Cycle 8 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CLss) of serum rituximab</measure>
    <time_frame>Cycle 1 through Cycle 8 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of rituximab</measure>
    <time_frame>Cycle 1 through Cycle 8 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of rituximab</measure>
    <time_frame>Cycle 1 through Cycle 8 (one Cycle=21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR) as determined by the Independent Review Committee (IRC) using Lugano Response Criteria for Malignant Lymphoma</measure>
    <time_frame>6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR, as determined by IRC using International Working Group (IWG) Response Criteria for NHL 1999 Guidelines</measure>
    <time_frame>6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation</time_frame>
    <description>CRR is defined as complete response (CR) or complete response unconfirmed (CRu)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR, as determined by the investigator using Lugano Response Criteria for Malignant Lymphoma</measure>
    <time_frame>6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR), as determined by investigator and IRC using Lugano Response Criteria for Malignant Lymphoma</measure>
    <time_frame>6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation</time_frame>
    <description>ORR is defined as complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>6 months after the last dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with rituximab administration-related reactions (ARRs)</measure>
    <time_frame>6 months after the last dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-drug antibodies (ADAs)</measure>
    <time_frame>6 months after the last dose of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 8 cycles of IV rituximab in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 cycle of IV plus 7 cycles of SC in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab IV</intervention_name>
    <description>Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m2 (milligram per square meter)</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab SC</intervention_name>
    <description>Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg)</description>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab IV</intervention_name>
    <description>Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m2</description>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered IV at a dose of 750 mg/m2</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin will be administered IV at a dose of 50 mg/m2</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine will be administered IV at a dose of 1.4 mg/m2</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered orally at a dose of 100 mg/day</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine hydrochloride or alternative antihistamine</intervention_name>
    <description>All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab</description>
    <arm_group_label>Rituximab IV+CHOP</arm_group_label>
    <arm_group_label>Rituximab SC+CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL)&#xD;
&#xD;
          -  Participants with an International Prognostic Index (IPI) score of 1 to 5 or IPI score&#xD;
             of 0 with bulky disease, defined as one lesion &gt;/=7.5 cm&#xD;
&#xD;
          -  At least one bi-dimensionally measurable lesion defined as &gt;/=1.5 cm in its largest&#xD;
             dimension on CT scan&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;/=50% on cardiac multiple-gated acquisition&#xD;
             (MUGA) scan or cardiac echocardiogram&#xD;
&#xD;
          -  A negative serum pregnancy test or a negative urine pregnancy test within 7 days prior&#xD;
             to study treatment&#xD;
&#xD;
          -  For men who are not surgically sterile, agreement to use a barrier method of&#xD;
             contraception during the treatment period and until &gt;/=12 months after the last dose&#xD;
             of rituximab SC or rituximab IV or according to institutional guidelines for CHOP&#xD;
             chemotherapy, whichever is longer, and agreement to request that their partners use an&#xD;
             additional method of contraception&#xD;
&#xD;
          -  For women of reproductive potential who are not surgically sterile, agreement to use&#xD;
             adequate methods of contraception during the treatment period and until &gt;/=12 months&#xD;
             after the last dose of rituximab SC or rituximab IV or according to institutional&#xD;
             guidelines for CHOP chemotherapy, whichever is longer&#xD;
&#xD;
          -  Adequate hematologic function confirmed within 14 days prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transformed non-Hodgkin's lymphoma (NHL) or types of NHL other than DLBCL and its&#xD;
             subtypes according to World Health Organization classification&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies or known sensitivity or allergy to murine products&#xD;
&#xD;
          -  Contraindication to any of the individual components of CHOP, including prior receipt&#xD;
             of anthracyclines&#xD;
&#xD;
          -  Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation or&#xD;
             surgery for diagnosis&#xD;
&#xD;
          -  Prior treatment with cytotoxic drugs or rituximab for another condition&#xD;
             (e.g.,rheumatoid arthritis) or prior use of an anti-CD20 antibody&#xD;
&#xD;
          -  Current or recent treatment with another investigational drug or participation in&#xD;
             another investigational therapeutic study&#xD;
&#xD;
          -  Ongoing corticosteroid use (&gt;30 mg/day of prednisone or equivalent)&#xD;
&#xD;
          -  Primary CNS lymphoma, blastic variant of mantle cell lymphoma, or histologic evidence&#xD;
             of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion&#xD;
             lymphoma, and primary cutaneous DLBCL&#xD;
&#xD;
          -  History of other malignancy that could affect compliance with the protocol or&#xD;
             interpretation of results&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases including but not limited&#xD;
             to significant cardiovascular disease or pulmonary disease&#xD;
&#xD;
          -  Any of the following abnormal laboratory values: creatinine &gt;1.5 upper limit of normal&#xD;
             (ULN), aspartate aminotransferase (AST) / alanine aminotransferase (ALT) &gt;2.5ULN,&#xD;
             total bilirubin &gt;1.5ULN, prothrombin time - international normalized ratio (PT-INR) /&#xD;
             partial thromboplastin time (PTT) / activated partial thromboplastin time&#xD;
             (aPTT)&gt;1.5ULN&#xD;
&#xD;
          -  Positive test results for chronic hepatitis B (HBV) and or hepatitis C (HCV)&#xD;
             infection; Participants with occult or prior HBV infection (defined as negative HBsAg&#xD;
             and positive total hepatitis B core antibody [HBcAb]) may be included if HBV DNA is&#xD;
             undetectable; Participants positive for HCV antibody are eligible only if polymerase&#xD;
             chain reaction (PCR) is negative for HCV RNA&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: YO42207 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun City</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital - Sichuan University</name>
      <address>
        <city>Chengdu City</city>
        <zip>610047</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou City</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Nanchang Unversity</name>
      <address>
        <city>Nanchang City</city>
        <zip>330200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjing</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan City</city>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xian Jiao Tong University</name>
      <address>
        <city>Xi'an City</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mabthera, Rituximab, SC, Subcutaneous, DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

